



Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England

D. Lee¹ · A. Amadi² · J. Sabater³ · J. Ellis² · H. Johnson⁴ · S. Kotapati³ · S. McNamara⁵ · A. Walker⁶ · M. Cooper¹ · K. Patterson¹ · N. Roskell¹ · Y. Meng¹

Published online: 11 September 2018
© The Author(s) 2018. This article is an open access publication

Correction to: Pharmacoeconomics Open
<https://doi.org/10.1007/s41669-018-0080-5>

The second Key Point for Decision Makers, which reads:

“Assuming equal post-progression survival between comparators of similar mechanism of action or using data from earlier data-cuts can provide comparable incremental cost-effectiveness ratios to those calculated in the absence of overall survival data”

should read:

“Assuming equal post-progression survival between comparators of similar mechanism of action or using data from earlier data-cuts can provide comparable incremental cost-effectiveness ratios to those calculated using overall survival data”

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s41669-018-0080-5>.

✉ D. Lee
dlee@bresmed.com

¹ BresMed Health Solutions, Sheffield, UK

² Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK

³ Bristol-Myers Squibb, Princeton, NJ, USA

⁴ Helen Johnson Consulting Ltd, Welwyn Garden City, UK

⁵ School of Health and Related Research, University of Sheffield, Sheffield, UK

⁶ Salus Alba, Glasgow, UK